Eletriptan

Active ingredient: Eletriptan Hydrobromide

In short: Eletriptan Hydrobromide Tablets is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established.

Forms & strengths20 mg Tablets: An orange color, round, biconvex shaped, film-coated tablet debossed ‘B02’ on one side and plain on the other side. 40 mg Tablets: An orange color, round, biconvex shaped, film-coated tablet debossed ‘B119’ on one side and plain on the other …
LabelApnar Pharma LP
Label updatedMay 21, 2026

What is Eletriptan used for?

Eletriptan Hydrobromide Tablets is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use:

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with Eletriptan Hydrobromide Tablets, reconsider the diagnosis of migraine before Eletriptan Hydrobromide Tablets is administered to treat any subsequent attacks.

Eletriptan Hydrobromide Tablets is not intended for the prevention of migraine attacks.

Safety and effectiveness of Eletriptan Hydrobromide Tablets have not been established for cluster headache.

Eletriptan dosage

The maximum recommended single dose is 40 mg.

In controlled clinical trials, single doses of 20 mg and 40 mg were effective for the acute treatment of migraine in adults. A greater proportion of patients had a response following a 40 mg dose than following a 20 mg dose .

If the migraine has not resolved by 2 hours after taking Eletriptan Hydrobromide Tablets, or returns after transient improvement, a second dose may be administered at least 2 hours after the first dose. The maximum daily dose should not exceed 80 mg.

The safety of treating an average of more than 3 migraine attacks in a 30-day period has not been established.

How to take Eletriptan — instructions & advice from the label

See FDA Approved Patient Labeling (Patient Information)

Myocardial Ischemia and/or Infarction, Prinzmetal's Angina, Other Vasospastic Reactions, and Cerebrovascular Events

Inform patients that Eletriptan Hydrobromide Tablets may cause serious cardiovascular adverse reactions such as myocardial infarction or stroke, which may result in hospitalization and even death. Although serious cardiovascular reactions can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and instruct them to ask for medical advice when observing any indicative sign or symptoms. Instruct patients to seek medical advice if they have symptoms of other vasospastic reactions .

Anaphylactic/Anaphylactoid Reactions

Inform patients that anaphylactic/anaphylactoid reactions have occurred in patients receiving Eletriptan Hydrobromide Tablets. Such reactions can be life threatening or fatal. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens . …

Warnings & precautions

Do not take this medicine if: Eletriptan Hydrobromide Tablets is contraindicated in patients with:

Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina .

Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders .

History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke .

Peripheral vascular disease .

Ischemic bowel disease .

Uncontrolled hypertension .

Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine1 (5-HT1) agonist, ergotamine-containing medication, or ergot-type medication such as dihydroergotamine (DHE) or methysergide .

Hypersensitivity to Eletriptan Hydrobromide Tablets (angioedema and anaphylaxis seen) .

Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir .

Eletriptan Hydrobromide Tablets should only be used where a clear diagnosis of migraine has been established.

Eletriptan Hydrobromide Tablets is contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of Eletriptan Hydrobromide Tablets. Some of these reactions occurred in patients without known CAD. Eletriptan Hydrobromide Tablets may cause coronary artery vasospasm (Prinzmetal's angina), even in patients without a history of CAD. …

Eletriptan side effects

The following adverse reactions are described elsewhere in other sections of the prescribing information:

Myocardial ischemia and myocardial infarction, and Prinzmetal's angina

Arrhythmias

Chest, throat, neck, and/or jaw pain/tightness/pressure

Cerebrovascular events

Other vasospasm reactions

Medication overuse headache

Serotonin syndrome

Increase in blood pressure

Hypersensitivity reactions

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Among 4,597 patients who treated the first migraine headache with Eletriptan Hydrobromide Tablets in short-term placebo-controlled trials, the most common adverse reactions reported with treatment with Eletriptan Hydrobromide Tablets were asthenia, nausea, dizziness, and somnolence. These reactions appear to be dose-related.

In long-term open-label studies where patients were allowed to treat multiple migraine attacks for up to 1 year, 128 (8.3%) out of 1,544 patients discontinued treatment due to adverse reactions.

Table 1 lists adverse reactions that occurred in the subset of 5,125 migraineurs who received eletriptan doses of 20 mg, 40 mg and 80 mg or placebo in worldwide placebo-controlled clinical trials. …

Drug interactions

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and Eletriptan Hydrobromide Tablets within 24 hours of each other is contraindicated. Concomitant use of other 5-HT1 agonists within 24 hours of Eletriptan Hydrobromide Tablets treatment is contraindicated .

Potent CYP3A4 inhibitors significantly increase the exposure of Eletriptan Hydrobromide Tablets. Eletriptan Hydrobromide Tablets should not be used within at least 72 hours of treatment with potent CYP3A4 inhibitors .

Cases of serotonin syndrome have been reported during co-administration of triptans and SSRIs, SNRIs, TCAs and MAO inhibitors .

About this medicine

Eletriptan Hydrobromide Tablets (eletriptan hydrobromide) contain eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Eletriptan hydrobromide is chemically designated as (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole monohydrobromide, and it has the following chemical structure:

The empirical formula is C

22

H

26

N

2

O

2

S . HBr, representing a molecular weight of 463.43. Eletriptan hydrobromide is a white to light pale colored powder that is readily soluble in water.

Each Eletriptan Hydrobromide Tablets Tablet for oral administration contains 25.17 mg or 50.34 mg of eletriptan hydrobromide equivalent to 20 mg or 40 mg of eletriptan, respectively. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 49686c51-bbd9-45f0-92b1-8ffa81612e35. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine